Pluristem Life Systems to Present at the Noble Financial Two Double-0-Seven Small Cap Equity Conference
NEW YORK, NY, Aug 17, 2007 (MARKET WIRE via COMTEX) -- Pluristem Life Systems, Inc. (OTCBB: PLRS) (DAX: PJT), a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today it will present at the Noble Financial Equity Conference on Monday, August 20, 2007 at 12:00 PM ET at the Charleston Place Hotel in Charleston, South Carolina.
William R. Prather RPh, MD, Senior Vice President Corporate Development, will give a 25-minute presentation regarding Pluristem's history, technology and growth prospects. A question and answer session will follow the presentation and one-on-one meetings with investors will be held throughout the day.
The presentation with streaming video and PowerPoint presentation will be webcast live on Noble Financial's conference website at www.two-007.net. It will also be archived on Pluristem's website at www.pluristem.com. It is recommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access.
Pluristem Life Systems, Inc. (OTCBB: PLRS) is a biotechnology company dedicated to the commercialization of allogeneic stem cell therapy products for the treatment of several severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-I, targets a $2 billion market and intends to resolve the global shortfall of matched tissue for bone marrow transplantation by improving the engraftment of umbilical cord blood (UCB). Pluristem's products are derived from mesenchymal stem cells obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors or cytokines. Pluristem believes the resultant expanded cells are multipotent and able to differentiate into a variety of different cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. |
